Literature DB >> 16223891

Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells.

Kevin P Langton1, Norman McKie, Brenda M Smith, Nicola J Brown, Michael D Barker.   

Abstract

Sorsby's fundus dystrophy (SFD) is an autosomal dominant degenerative disease of the retina, caused by mutations in exon 5 of the gene for tissue inhibitor of metalloproteinases-3 (TIMP-3). The mechanism by which these mutations give rise to the disease phenotype is unknown. In an attempt to identify common properties of these molecules that might underlie the disease phenotype, a range of SFD mutants were expressed from human retinal pigment epithelial (RPE) cells. This showed that resistance to turnover, resulting from intermolecular disulfide bond formation, was a common property of all the SFD mutants examined, providing a possible explanation for the increased deposition of the protein observed in eyes from SFD patients. In contrast, SFD mutants varied in their ability to inhibit cell-surface activation of matrix metalloproteinase-2 (MMP-2), a potent mediator of angiogenesis, ranging from being fully active to totally inactive. These data show that increased deposition of active TIMP-3, rather than dysregulation of metalloproteinase inhibition, is likely to be the primary, initiating event in SFD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223891     DOI: 10.1093/hmg/ddi385

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  19 in total

Review 1.  Recent advances in the dark adaptation investigations.

Authors:  Guo-Qing Yang; Tao Chen; Ye Tao; Zuo-Ming Zhang
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

2.  A novel TIMP3 mutation associated with a retinitis pigmentosa-like phenotype.

Authors:  Meghan J DeBenedictis; Yosef Gindzin; Enrico Glaab; Bela Anand-Apte
Journal:  Ophthalmic Genet       Date:  2020-07-27       Impact factor: 1.803

3.  Matrix bound SFD mutant TIMP-3 is more stable than wild type TIMP-3.

Authors:  Mohammed A Majid; Valerie A Smith; Andrew C Newby; Andrew D Dick
Journal:  Br J Ophthalmol       Date:  2007-03-23       Impact factor: 4.638

4.  Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3.

Authors:  Quteba Ebrahem; Jian Hua Qi; Masahiko Sugimoto; Mariya Ali; Jonathan E Sears; Alecia Cutler; Rama Khokha; Amit Vasanji; Bela Anand-Apte
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-03       Impact factor: 4.799

Review 5.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

Review 6.  Sorsby fundus dystrophy: Insights from the past and looking to the future.

Authors:  Bela Anand-Apte; Jennifer R Chao; Ruchira Singh; Heidi Stöhr
Journal:  J Neurosci Res       Date:  2018-08-21       Impact factor: 4.164

7.  S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis.

Authors:  Jian Hua Qi; Ganying Dai; Philip Luthert; Shyam Chaurasia; Joe Hollyfield; Bernhard H F Weber; Heidi Stöhr; Bela Anand-Apte
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

Review 8.  Looking into the future: Using induced pluripotent stem cells to build two and three dimensional ocular tissue for cell therapy and disease modeling.

Authors:  Min Jae Song; Kapil Bharti
Journal:  Brain Res       Date:  2015-12-17       Impact factor: 3.252

Review 9.  Visual Outcome after Intravitreal Anti-VEGF Therapy for Macular Neovascularisation Secondary to Sorsby's Fundus Dystrophy: A Systematic Review.

Authors:  Arthur Baston; Christin Gerhardt; Souska Zandi; Justus G Garweg
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

10.  Secretory defect and cytotoxicity: the potential disease mechanisms for the retinitis pigmentosa (RP)-associated interphotoreceptor retinoid-binding protein (IRBP).

Authors:  Songhua Li; Zhihui Yang; Jane Hu; William C Gordon; Nicolas G Bazan; Arthur L Haas; Dean Bok; Minghao Jin
Journal:  J Biol Chem       Date:  2013-03-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.